Loading...
XTSXMIR
Market cap44mUSD
Dec 23, Last price  
0.08CAD
1D
-11.76%
1Q
-6.25%
Jan 2017
150.00%
Name

MedMira Inc

Chart & Performance

D1W1MN
XTSX:MIR chart
P/E
—
P/S
156.23
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.28%
Rev. gr., 5y
-4.79%
Revenues
413k
-4.61%
2,660,6972,091,4161,705,3211,524,5191,137,6451,073,175909,869970,6312,001,4642,528,1794,052,3412,256,832747,344588,871527,445919,0722,144,470952,127432,529412,568
Net income
-3m
L+24.32%
-6,106,592-7,287,759-6,287,523-7,018,042-5,263,171-4,418,662-4,892,1833,372,302-402,301-3,835,339-3,229,565-5,158,401-2,661,067-2,509,464-2,106,448-2,045,386-675,797-1,831,576-2,675,658-3,326,321
CFO
-3m
L+131.79%
-5,372,312-7,536,696-2,103,310-3,232,228-2,022,820-2,637,317-1,692,982000-2,346,327-4,092,556-1,890,267-795,406-941,131-315,896-504,639-1,883,956-1,267,750-2,938,521
Earnings
Mar 31, 2025

Profile

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
URL
https://medmira.com/
IPO date
Dec 01, 1999
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑07
Income
Revenues
413
-4.61%
433
-54.57%
952
-55.60%
Cost of revenue
2,142
2,377
1,589
Unusual Expense (Income)
NOPBT
(1,730)
(1,944)
(637)
NOPBT Margin
Operating Taxes
174
Tax Rate
NOPAT
(1,730)
(1,944)
(810)
Net income
(3,326)
24.32%
(2,676)
46.09%
(1,832)
171.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,666
BB yield
-1.88%
Debt
Debt current
6,408
6,314
6,251
Long-term debt
5,710
4,965
4,207
Deferred revenue
Other long-term liabilities
(2)
Net debt
10,020
11,266
10,425
Cash flow
Cash from operating activities
(2,939)
(1,268)
(1,884)
CAPEX
(743)
(1)
(70)
Cash from investing activities
(743)
(1)
(70)
Cash from financing activities
5,765
1,249
1,987
FCF
986
(241)
(942)
Balance
Cash
2,098
13
33
Long term investments
Excess cash
2,077
Stockholders' equity
(18,037)
(15,032)
(12,353)
Invested Capital
9,560
9,271
8,297
ROIC
ROCE
20.41%
33.75%
15.69%
EV
Common stock shares outstanding
701,731
697,446
680,646
Price
0.10
5.56%
0.09
-30.77%
0.13
8.33%
Market cap
66,664
6.20%
62,770
-29.06%
88,484
12.01%
EV
76,685
74,038
98,911
EBITDA
(1,420)
(1,731)
(424)
EV/EBITDA
Interest
882
886
552
Interest/NOPBT